neurodegenerative diseases

A Lancet Commission study in 2020 estimated that hearing loss is associated with 8% of dementia cases worldwide. Now, a paper has analysed data from more than 400,000 people collected at the UK Biobank. Their findings show that the risk of developing dementia is 42% higher in people with hearing problems, but this increased risk disappears in those who use hearing aids. According to the authors, whose work is published in The Lancet Public Health, the data "highlight the urgent need to introduce hearing aids early when someone starts to experience hearing problems".

Swedish research involving more than 6,000 male footballers in the country's top division (between 1924 and 2019) indicates that they were 1.5 times more likely to develop a neurodegenerative disease compared to the population analysed who were not involved in professional football. Unlike outfield players, goalkeepers did not have this increased risk, which, according to the authors, supports the hypothesis that impacts to the head when striking the ball could explain the increased risk. The study is published in The Lancet Public Health.

A study published in the journal Neurology claims to have confirmed the usefulness of a biomarker in blood to diagnose Alzheimer's disease without the need for other tests.

A few weeks ago, a press release from the Biogen and Eisai companies reported significant results from their lecanemab antibody for the treatment of early-stage Alzheimer's. The data from the phase 3 trial are now published in the New England Journal of Medicine, coinciding with the CTAD conference on Alzheimer's disease clinical trials in San Francisco. Data from the phase 3 clinical trial are now published in the New England Journal of Medicine, coinciding with the 15th CTAD Alzheimer's disease clinical trials conference in San Francisco.

People with Down syndrome are at high risk of developing dementia very similar to that caused by Alzheimer's disease. A study published in the journal PNAS has found that in these people, as had been observed in "classic" Alzheimer's, the characteristic proteins of the disease have prion-like features.

The New England Journal of Medicine reports the publication of data from a clinical trial studying the drug Tofersen against a form of Amyotrophic Lateral Sclerosis (ALS) caused by mutations in the SOD1 gene, which accounts for 2% of sporadic ALS. Six months after treatment, some biomarkers of neuronal damage improved, but not the clinical condition of the patients. In an extension of the study, with no placebo group, a slowing of functional loss was observed, although the researchers acknowledge that there are limitations in interpreting this result.

Scientists have analysed data on 7.1 million common DNA variants (alterations in the standard sequence) in people with and without Alzheimer's disease. The results, published in PLOS Genetics, have helped them to develop a method that can predict the risk of suffering from this neurodegenerative disease, depending on the DNA variants that a person has and before presenting symptoms.